Now Is A Suitable Moment For A Long-Term Purchase Of BioXcel Therapeutics Inc (NASDAQ: BTAI)
Currently, there are 28.15M common shares owned by the public and among those 20.68M shares have been available to trade. Insiders at the company have transacted a total of 42 times over the past 12 months, according to data filed with the U.S. Securities and Exchange Commission (SEC). 23 of these insider trades were purchases, […]
BioXcel Therapeutics Inc (BTAI): A Great Stock For Handling Current Market Conditions?
The Vanguard Group, Inc. recently announced the acquisition of new stake in BioXcel Therapeutics Inc (NASDAQ:BTAI). The institutional investor has increased its shareholding in the Healthcare company by 8.54% to 1.16 million shares with purchase of 91600.0 shares. This fresh investment now brings its stake to 3.98% valued currently at $3.43 million. In addition, Columbia […]
